v3.26.3
Segment Reporting (Tables)
 9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Segment Reporting
The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):
Three months ended September 30,Nine months ended September 30,
2026202520262025
Collaborative arrangement revenue$1,951 $1,752 $4,973 $4,606 
Less:
OCU4002,986 3,616 6,502 7,463 
OCU410 and OCU410ST2,834 1,373 6,799 3,675 
NeoCart61 19 279 25 
COVAXIN3 — 13 — 
Inhaled mucosal vaccine platform145 67 224 399 
OCU20047 131 307 530 
Unallocated costs:
Research and development personnel costs5,284 4,353 16,036 12,454 
Facilities and other support costs837 864 2,646 2,665 
Other303 726 1,639 1,870 
Total research and development12,500 11,149 34,445 29,081 
General and administrative7,204 8,228 22,563 21,446 
Total operating expenses19,704 19,377 57,008 50,527 
Loss from operations(17,753)(17,625)(52,035)(45,921)
Other income (expense):
Interest Income649 207 1,174 778 
Interest Expense(3,090)(1,314)(8,886)(3,856)
Loss on extinguishment of debt— — (2,383)— 
Change in fair value of derivative liability16,562 — 14,671 — 
   Other (expense) income, net34 (1,319)(194)(1,141)
        Total other (expense) income14,155 (2,426)4,382 (4,219)
Segment and consolidated net loss$(3,598)$(20,051)$(47,653)$(50,140)